EVOLVING SEPTAL
CLOSURE

EVOLVING SEPTAL CLOSURE

Less metal, more options for the future

Less metal, more options for the future

The reSept™ ASD Occluder is the first occluder with a metal-free frame designed for the closure of atrial septal defects.

EVOLVING
SEPTAL CLOSURE

Less metal, more options for the future

The reSept™ ASD Occluder is the first and only occluder with a metal-free frame designed for the closure of atrial septal defects.
Hole in the heart

ASD hole size

S = Small, M = Medium, L = Large

DEFECTS VARY IN SIZE AND POSITION

  • Very small defects may be found by chance and may never cause a problem.
  • Some may close on their own during childhood.
  • Medium and large defects may require a medical procedure to be closed.

When ASDs require closure, the current standard of care is to have an atrial septal occluder implanted through a minimally invasive procedure, which does not require opening the heart. However, open heart surgery may be required in some cases, based on the size and position of the defect.

ASCENT-ASD

ATRIAL SEPTAL OCCLUDERS HELP CLOSE DEFECTS

  • The occluder is introduced by a catheter through a small incision in the groin and positioned in the heart.
  • Once in place, the occluder is deployed to seal the hole and prevent abnormal blood flow between the upper chambers of the heart.

Septal occluders have enabled minimally invasive treatment; however, currently available options have limitations because of their bulky, dense metal frames. 
The long-term presence of dense metal in the heart may lead to potential complications and may limit future interventions that require a physician to cross the septum.

LESS METAL, MORE OPTIONS

The reSept™ ASD Occluder is the first device with a metal-free, bioresorbable frame. This novel device aims to overcome the limitations of current ASD treatment options and offers the potential to:

  • Help reduce the risk of complications due to long-term presence of bulky metal in the heart.
  • Enable future interventions that may not otherwise be possible due to metal barriers.
LESS METAL, MORE OPTIONS
The reSept ASD Occluder is the first and only device with a metal-free, bioresorbable frame. This novel device aims to overcome the limitations of current ASD treatment options and offers the potential to:
  • Help reduce the risk of complications due to long-term presence of bulky metal in the heart.
  • Enable future interventions that may not otherwise be possible due to metal barriers.
LESS METAL, MORE OPTIONS
The reSept™ ASD Occluder is the first and only device with a metal-free, bioresorbable frame. This novel device aims to overcome the limitations of current ASD treatment options and offers the potential to:
  • Help reduce the risk of complications due to long-term presence of bulky metal in the heart.
  • Enable future interventions that may not otherwise be possible due to metal barriers.
The reSept ASD Occluder
features bioresorbable filaments connecting two polyester fabric patches
Closure

How it works

RESULTS SO FAR

First In Human Study: Nine adult patients have been implanted with our ASD Occluder and had their ASDs successfully closed. The first patient was implanted over five years ago. The study was conducted in Germany.

European Registry: Six patients, including four children, have been implanted with our ASD Occluder and had their ASDs successfully closed. The first patient was implanted in March 2020. The registry was conducted in Germany and Switzerland.

ASCENT-ASD
Investigational device exemption (IDE) U.S. trial

atHeart Medical has initiated a pivotal trial in the United States to demonstrate the safety and efficacy of its reSept ASD Occluder for treating patients with clinically significant, isolated ASD.

For more information about the study and participating hospitals, please visit clinicaltrials.gov (NCT04591392).

RESULTS SO FAR

First In Human Study: Nine adult patients have been implanted with our ASD Occluder and had their ASDs successfully closed. The first patient was implanted over five years ago. The study was conducted in Germany.

European Registry: Six patients, including four children, have been implanted with our ASD Occluder and had their ASDs successfully closed. The first patient was implanted in March 2020. The registry was conducted in Germany and Switzerland.

ASCENT-ASD investigational device exemption (IDE) U.S. trial

atHeart Medical has initiated a pivotal trial in the United States to demonstrate the safety and efficacy of its reSept ASD Occluder for treating patients with clinically significant, isolated ASD.

For more information about the study and participating hospitals, please visit clinicaltrials.gov (NCT04591392).

atHeart Medical

Our mission is to establish the first transcatheter ASD occluder with a metal-free frame as the new standard of care for atrial septal defects (ASDs).

Based in Switzerland and in the U.S., we have assembled an exceptional team with decades of experience at medical device start-ups and major corporations.

We have initiated our ASCENT-ASD pivotal trial in the United States and internationally to demonstrate the safety and efficacy of our reSept ASD Occluder for treating patients with clinically significant, isolated ASD. Our reSept ASD Occluder has received Investigational Device Exemption approval from the U.S. FDA.

Our company was founded by the Olle Larsson Holding AG (OLH), a Swiss corporate group with a diverse portfolio of companies in medical devices, among other sectors. Our ASD occluder was initially developed by Carag, a Swiss engineering and consulting firm, also an OLH company.